Evaluation of the Microbial Growth Potential of Pharmaceutical Drug Products and Quality by Design

References

1. 1.↵
   AAPS Workshop on Pharmaceutical Quality Assessment—A Science and Risk-Based CMC Approach in the 21^st Century; North Bethesda, MD, October 5–7, 2005.
2. 2.↵
   Federal Register, Vol. 70, No. 134; 2005. U.S. Department of Health and Human Services, Food and Drug Administration. Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality Assessment System; Notice of Pilot Program.
3. 3.↵
   Federal Register, Vol. 73, No. 128; 2008. U.S. Department of Health and Human Services, Food and Drug Administration. Submission of Quality Information for Biotechnology Products in the Office of Biotechnology Products; Notice of Pilot Program.
4. 4.↵
   U.S. Department of Health and Human Services, Food and Drug Administration. International Conference on Harmonization, Guidance for Industry: Q8 Pharmaceutical Development (2006) and Q8(R1) Pharmaceutical Development Revision 1 (2007). Rockville, MD.
5. 5.↵
   1. Metcalfe J. W.

   Microbiological quality of drug products after penetration of the container system for dose preparation prior to patient administration. American Pharmaceutical Review 2009, 12 (1), 84–89.

   OpenUrl
6. 6.↵
   1. Friedel R. R.,
   2. Cundell A. M.

   The application of water activity measurement to the microbiological attributes testing of nonsterile over-the-counter drug products. Pharmacopeial Forum 1998, 24 (2), 6087–6090.

   OpenUrl
7. 7.↵
   1. Fontana A. J.

   Understanding water activity for reduced microbial testing using USP Method 〈1112〉. Pharmaceutical Microbiology Forum Newsletter 2006, 12 (10), 2–5.

   OpenUrl
8. 8.↵
   United States Pharmacopeia—National Formulary (USP 29-NF 24) 2006. 〈1112〉 Application of Water Activity Determination to Nonsterile Pharmaceutical Products. Washington, D.C., p. 3802–3803.
9. 9.↵
   1. Snider B.,
   2. Liang P.,
   3. Pearson N.

   Implementation of water-activity testing to replace Karl Fischer water testing for solid oral-dosage forms. Pharmaceutical Technology 2007, 31 (2).
10. 10.↵
    U.S. Department of Health and Human Services, Food and Drug Administration. International Conference on Harmonization, Guidance on Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Rockville, MD, 2000.
11. 11.↵
    U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes. Rockville, MD, 2010.
12. 12.↵
    1. Noecker R.

    Effects of common ophthalmic preservatives on ocular health. Adv. Ther. 2001, 18 (5), 205–215.

    OpenUrlPubMedWeb of Science
13. 13.↵
    1. Graf P.,
    2. Hallen H.,
    3. Juto J.-E.

    Benzalkonium chloride in a decongestant nasal spray aggravates rhinitis medicamentosa in healthy volunteers. Clin. Exp. Allergy 1995, 25 (5), 395–400.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Perrenoud D.,
    2. Bircher A.,
    3. Hunziker T.,
    4. Suter H.,
    5. Bruckner-Tuderman L.,
    6. Stäger J.,
    7. Thürlimann W.,
    8. Schmid P.,
    9. Suard A.,
    10. Hunziker N.

    Frequency of sensitization to 13 common preservatives in Switzerland. Contact Dermatitis 1994, 30 (5), 276–279.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    Anonymous. Infections linked to lax handling of propofol. Am. J. Health Syst. Pharm. 1995, 52 (19), 2061–2066.

    OpenUrlPubMed
16. 16.↵
    1. McNeil M. M.,
    2. Lasker B. A.,
    3. Lott T. J.,
    4. Jarvis W. R.

    Postsurgical Candida albicans infections associated with an extrinsically contaminated intravenous anesthetic agent. J. Clin. Microbiol. 1999, 37 (5), 1398–1403.

    OpenUrlAbstract/FREE Full Text